SPC protection for combinations
Many drugs, including vaccines, oncology therapies, anti-asthmatics and hypertensives, are administered as combinations of active ingredients. This is due to a number of different reasons ranging from policy to synergistic interaction. Combination drugs may also require substantial investment, even when one or both components have themselves been available as separate treatments for many years. In many circumstances, this has led those that manufacture and sell such drugs to seek supplementary protection certificates (SPCs) to preserve protection and thus protect the investment in the drug from generic competition.
The difficulty for these applicants is that it has proved very difficult to interpret the legislation governing SPCs — Council Regulation (EEC) No 1768/92 (SPC regulation) — as regards combination drugs. This is widely thought to be because the SPC regulation was only drafted to deal with those drugs comprising single, small-molecule active ingredients.
This problem primarily lies with Article 3, which deals with the qualifying criteria for SPC protection…
If you are registered and logged in to the site, click on the link below to read the rest of the Taylor Wessing briefing. If not, please register or sign in with your details below.
News from Taylor Wessing
News from The Lawyer
Briefings from Taylor Wessing
When entering into corporate and commercial contracts, it is common to structure the deal so that if there is a breach it can be compensated without having to bring court proceedings.
In the current market, private equity sponsors are increasingly looking at initial public offerings (IPOs) as a real exit option for their portfolio investments.
Analysis from The Lawyer
The city-state is working hard to become a global wealth management hub, and law firms are gearing up for a prosperous new world
Financial disputes are starting to dominate the English courts as the long-awaited fallout from the downturn finally comes to town